Epigenica AB

Based in Sweden, Epigenica AB specializes in innovative solutions for epigenetic analysis, developing advanced technologies that support high-throughput analysis critical for biomedical research and drug discovery. Epigenica AB is a Swedish biotechnology firm founded in 2020, headquartered in Solna, Sweden. The company focuses on epigenetic analysis, with its flagship product, the EpiFinder™ platform, allowing concurrently high-throughput analysis of DNA methylation and histone modifications. In June 2025, Epigenica raised SEK 21.

5 million in a funding round led by Voima Ventures, with investments from ALMI Invest, Leksell Social Ventures, and Navigare Ventures, representing its first significant funding effort. The company has engaged in one deal to date, which illustrates its early growth phase. Epigenica specializes in innovative solutions for epigenetic analysis, primarily focusing on their flagship product, the EpiFinder™ platform. This advanced multiplexed ChIP-seq technology allows researchers to conduct high-throughput analysis of both DNA methylation (DNAm) and histone post-translational modifications (HPTMs) simultaneously, a significant advancement over existing technologies that typically restrict profiling to one type at a time.

The EpiFinder™ Genome kit enables comprehensive genome-wide profiling, allowing scientists to target up to eight epigenetic markers across 24 samples or replicates, generating a total of 192 quantitative ChIP-seq tracks from only 125,000 cells per track. Geographically, Epigenica’s products cater to a diverse clientele, including academic institutions, biotech and pharmaceutical companies, and research organizations across North America, Europe, and Asia, addressing critical needs in biomedical research, drug discovery, and precision medicine. Epigenica operates on a transaction model primarily structured around direct sales of their EpiFinder™ product line, which includes the EpiFinder™ Genome kit and upcoming offerings such as EpiFinder™ Global and EpiFinder™ cNUC. The company engages with clients in the biotechnology and pharmaceutical sectors, offering bespoke solutions tailored for high-throughput epigenetic research.

Transactions are executed through one-time purchases, where customers acquire kits that include necessary reagents and protocols for generating sequencing-ready libraries. The pricing structure reflects their innovative capabilities and the advanced technology incorporated, designed to facilitate advancements in research efficiency and data quality. Additionally, a customized analysis pipeline provided with the kits allows users to streamline their workflow, enhancing the overall value proposition for end-users. In June 2025, Epigenica raised SEK 21.

5 million in venture funding led by Voima Ventures, with participation from Navigare Ventures and Leksell Social Ventures. The company plans to utilize this funding to further develop its epigenetic product portfolio, expand its service infrastructure, and enter the US market. Upcoming products include EpiFinder™ Global and EpiFinder™ cNUC, which are expected to enhance their offerings. The expansion into the US market is a strategic move aimed at increasing their global footprint and addressing the demands of a larger client base.